** Biotech firm Aligos Therapeutics'ALGS.O shares fall 17.3% to $10.70, hit three-month low
** Company posts quarterly net loss of $13.08 per share vs loss of $5.50 per share a year earlier
** Reports cash equivalents and investments in 2024 of $56.9 million vs $135.7 million in 2023, which will provide sufficient funding of planned operations into H2 2026
** Company says it is continuing to evaluate a variety of options to fund continued development of its liver disease drug, including potential out-licensing
** As of last close, ALGS has fallen 44.3% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。